Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Total revenues		$ 117,029
Cost of revenues		(117,029)
Operating expenses:
Research and development	$ 2,227,175	1,095,040
General and administrative	1,084,828	1,022,051
Total operating expenses	3,312,003	2,117,091
Loss from operations	(3,312,003)	(2,117,091)
Other income (expense):
Foreign currency transaction (loss) gain	(788)	1,209
Interest income, net	76,028	28,842
Research and development incentives		6,331
Change in fair value of convertible debt		165,382
Total other income	75,240	201,764
Net loss before income taxes	(3,236,763)	(1,915,327)
Net loss applicable to common stockholders	$ (3,236,763)	$ (1,915,327)
Basic net loss per share (in Dollars per share)	$ (1.06)	$ (2.91)
Diluted net loss per share (in Dollars per share)	$ (1.06)	$ (2.91)
Basic weighted average common shares outstanding (in Shares)	3,049,625	657,698
Diluted weighted average common shares outstanding (in Shares)	3,049,625	657,698
Grant revenue
Total revenues		$ 117,029